When FDA Trust Is Broken: Lessons from the MedLink Scandal

MedDevice by Design with Mark Drlik and Ariana Wilson
Resources

When FDA Trust Is Broken: Lessons from the MedLink Scandal

Sector: Diagnostics
YouTube video thumbnail

A recent FDA announcement has sent shockwaves through the MedTech community: MedLink, a third-party test house, was found falsifying test data. The consequences? All pending FDA submissions that relied on MedLink’s data have been rejected, delaying or derailing device approvals and costing companies precious time and trust.

In this episode of MedDevice by Design, Ariana Wilson and Mark Drlik examine what happened, what it means for medical device innovators, and how the FDA’s ASCA (Accreditation Scheme for Conformity Assessment) program helps reduce regulatory risk.

The FDA discovered that MedLink had falsified testing data, compromising the integrity of submissions relying on that information. As a result, those submissions are now invalid, and the affected companies must retest their devices and resubmit, costing them months of delay and significant financial loss.

Why ASCA Accreditation Matters

To prevent this kind of disruption, the FDA established the ASCA program in 2020. Labs that receive ASCA accreditation are thoroughly vetted, giving the FDA and submitting companies greater confidence in their test results. Submissions that include ASCA-accredited data benefit from reduced review times—sometimes shaving weeks or even months off approval timelines.

The Tradeoff: Fewer Labs, Higher Costs

As of late 2024, only 47 test houses hold ASCA accreditation, limiting access for some companies. Additionally, ASCA-accredited testing can be 10% to 30% more expensive than non-accredited alternatives. Still, that investment offers peace of mind and regulatory security—especially when the risk of working with an unreliable lab is so high.

Key Takeaway: Prioritize Risk Management


This episode is a reminder of the critical role third-party labs play in the regulatory process. Choosing an ASCA-accredited lab is not just about speed; it’s about reducing risk, protecting your investment, and ensuring trust in your data.

Medical device pilot manufacturing workspace showing engineers supporting NPI and scalable production

In MedTech, success rarely comes from invention alone. Plenty of promising technologies make it through verification and early clinical work, only to stall when the team tries to turn them into something buildable.

Thumbnail showing bacterial growth from one cell to 10²¹ cells, illustrating rapid bacteria reproduction with text reading “This fast?” and a red arrow indicating exponential increase.

From how much of your body is actually bacterial to how fast microbes can multiply, these facts are designed to stick with you long after the party ends.

Engineer reviewing a systems workflow diagram representing proportional verification planning in medical device development

In medical device development, verification is both a safeguard and a stress test, not just for the product, but for the process.

Cross-functional MedTech team discussing requirements on a tablet during a medical device development meeting.

In the world of medical device development, requirements are often treated as a regulatory tax, essentially documentation created solely to satisfy a compliance need.